China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization

Condition(s) studied

Investigational drug(s) / intervention(s)

No intervention; Observational study: No intervention; observational study

Study summary

Right heart catheterization(RHC) plays a crucial role in the diagnosis and treatment of pulmonary vascular diseases(PVD). In China, the lack of equipment and technical expertise has historically limited the implementation of RHC, thereby greatly restricting the diagnosis and treatment of RVD. In recent years, with improvements in these issues, more hospitals have acquired the capability to perform RHC. The purpose of this study is to conduct quality control of RHC across multiple pulmonary hypertension(PH) centers in China. The study population consists of patients who underwent RHC for the first time due to dyspnea or suspected PH. This study retrospectively and prospectively collects multicenter RHC data, with the main quality control contents including indications for the procedure, collection and analysis of hemodynamic data, diagnosis and treatment, and long-term management of patients.

Eligibility

Primary outcome measure(s)

• 3-month all cause death — 3 month
  3-month all cause death

Trial sites (1)

More China-Japan Friendship Hospital trials in Japan

Other trials for the same condition